Anti-antioxidant impacts of circZNF609 silence in HaCaT cells through regulating miR-145
Source abstract
Abstract
Background CircZNF609 (cZNF609) is previously revealed as an essential mediator in oxidative stress. This paper determined the role of cZNF609 in skin oxidative damage to evaluate its importance in pressure ulcer.Methods HaCaT cells treated by H2O2 were considered as a cell model of pressure ulcer. The role of cZNF609 in the model was checked by conducting CCK-8 assay, FITC-PI double-staining, ROS detection and Western blot. The downstream gene and signalling of cZNF609 were studied by utilizing qRT-PCR and Western blot.Results HaCaT cells were remarkably damaged by H2O2, as evidenced by the viability loss, apoptosis and ROS generation. It was coupled with the elevated expression of p53, p16, Bax and the activated forms of caspase-3 and PARP. Meanwhile, cZNF609 was high-expressed in response to H2O2. The oxidative stress driven by H2O2 was alleviated by transfection with cZNF609 specific siRNA. Further, the anti-antioxidant impacts of cZNF609 silence were impeded by miR-145 silence. The inhibition of JNK and p38MAPK pathways induced by cZNF609 silence was impeded by miR-145 silence.Conclusion The protective function of cZNF609 silence in H2O2-injured HaCaT cells was revealed in vitro. Silence of cZNF609 exhibited its impact possibly through regulating miR-145, and JNK and p38MAPK pathways.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Circular RNAs in diseases · MicroRNA in disease regulation · RNA regulation and disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Galactophore, Linyi Central Hospital
References (38)
Show source-provided references
1. 10.1016/j.ijnurstu.2015.06.00610.1016/j.ijnurstu.2015.06.006 ↗
2. 10.1177/026921631984602310.1177/0269216319846023 ↗
3. 10.1111/j.1532-5415.2009.02307.x10.1111/j.1532-5415.2009.02307.x ↗
4. Kottner J, Balzer K, Dassen T, et al. Pressure ulcers: a critical review of definitions and classifications. Ostomy Wound Manage. 2009;55(9):22–29.
5. 10.1016/j.jphs.2018.08.01310.1016/j.jphs.2018.08.013 ↗
6. 10.1016/j.yexmp.2019.10428110.1016/j.yexmp.2019.104281 ↗
7. 10.1080/15476286.2016.127152410.1080/15476286.2016.1271524 ↗
8. 10.1016/j.lfs.2019.11682610.1016/j.lfs.2019.116826 ↗
9. 10.1261/rna.043687.11310.1261/rna.043687.113 ↗
10. 10.1016/S0959-440X(00)00167-610.1016/S0959-440X(00)00167-6 ↗
11. 10.1161/CIRCRESAHA.115.30631910.1161/CIRCRESAHA.115.306319 ↗
12. 10.1016/j.molcel.2015.03.02710.1016/j.molcel.2015.03.027 ↗
13. 10.1016/j.molcel.2017.02.01710.1016/j.molcel.2017.02.017 ↗
14. Zhu L, Liu Y, Yang Y, et al. CircRNA ZNF609 promotes growth and metastasis of nasopharyngeal carcinoma by competing with microRNA-150-5p. Eur Rev Med Pharmacol Sci. 2019;23(7):2817–2826.
15. Wu L, Xia J, Yang J, et al. Circ-ZNF609 promotes migration of colorectal cancer by inhibiting Gli1 expression via microRNA-150. J BUON. 2018;23(5):1343–1349.
16. 10.1038/s41388-019-0699-410.1038/s41388-019-0699-4 ↗
17. 10.1002/jcp.2774410.1002/jcp.27744 ↗
18. 10.7150/thno.1935310.7150/thno.19353 ↗
19. Srinoun K, Sathirapongsasuti N, Paiboonsukwong K, et al. miR-144 regulates oxidative stress tolerance of thalassemic erythroid cell via targeting NRF2. Ann Hematol. 2019;98(9):2045–2052.
20. 10.1371/journal.pone.021846810.1371/journal.pone.0218468 ↗
21. 10.1016/j.yjmcc.2019.05.02010.1016/j.yjmcc.2019.05.020 ↗
22. 10.1016/j.mce.2017.05.03010.1016/j.mce.2017.05.030 ↗
23. 10.1016/j.lfs.2018.06.00510.1016/j.lfs.2018.06.005 ↗
24. 10.1016/j.ijnurstu.2012.11.01910.1016/j.ijnurstu.2012.11.019 ↗
25. 10.1016/j.yexmp.2018.12.00510.1016/j.yexmp.2018.12.005 ↗
26. 10.1136/svn-2018-00020610.1136/svn-2018-000206 ↗
27. 10.1684/ejd.2018.348310.1684/ejd.2018.3483 ↗
28. 10.1038/s41598-019-47189-210.1038/s41598-019-47189-2 ↗
29. 10.1159/00048595210.1159/000485952 ↗
30. 10.1111/bjd.1725610.1111/bjd.17256 ↗
31. 10.1177/205873841879594010.1177/2058738418795940 ↗
32. 10.1111/ced.1273610.1111/ced.12736 ↗
33. 10.7150/thno.2515610.7150/thno.25156 ↗
34. 10.18632/oncotarget.1365610.18632/oncotarget.13656 ↗
35. 10.2147/CMAR.S17477810.2147/CMAR.S174778 ↗
36. 10.4149/BLL_2018_05310.4149/BLL_2018_053 ↗
37. 10.1007/s00204-013-1034-410.1007/s00204-013-1034-4 ↗
38. 10.1089/ars.2016.664210.1089/ars.2016.6642 ↗